Small molecule trends to follow in 2023

[Clinical supply image courtesy of Lonza]

As the world begins to emerge from the pandemic, there are signs of an investment slowdown after record venture capital (VC) funding levels driven by COVID-19 treatment and prevention. “Even with this slowdown, we see that VC investment remains very high,” said Christian Dowdeswell, vice president, head of commercial development, small molecules at Lonza in an interview focused on small molecule trends.

The industry is yet to see a return to pre-pandemic levels in non-COVID-related clinical trials. “The biggest impact has been in Phase 1 trials, suggesting that there will be fewer drug candidates to progress into later phases of development,” Dowdeswell said. “That said, we still see high demand for CDMO services to support biotech companies in early-stage development.”

In the following interview, Dowdeswell provides perspective on which small molecule trends the …

Read more
  • 0